Alice Colombo
Research Subjects
Alice Colombo has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Alberto González-González
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Cantabria-IDIVAL, 39012 Santander, Spain
1 shared publication - Daniel García-Sánchez
Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Cantabria-IDIVAL, 39012 Santander, Spain
1 shared publication - Flor Maria Perez-Campo
University of Cantabria, Santandery Torrelavega, Spain
1 shared publication - Itziar Álvarez-Iglesias
Departamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain
1 shared publication - Luis Gil-De-Gómez
Departamento de Biología Molecular, Universidad de Cantabria-IDIVAL, 39011 Cantabria, Spain
1 shared publication
Latest Publications
- Open Access
- 23 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1155
Bridging Osteoimmunology and Regenerative Therapy: The Role of MSCs and Extracellular Vesicles
Bone homeostasis and regeneration depend on tightly regulated interactions between skeletal cells and the immune system within the bone microenvironment. Disruption of this crosstalk by ageing, chronic inflammation, or systemic disease contributes to osteoporosis, inflammatory bone loss, and impaired fracture healing. Osteoimmunology has reframed bone biology as an immune-regulated process, highlighting mesenchymal stem cells (MSCs) as central coordinators of bone-immune communication. Beyond their differentiation capacity, MSCs act primarily through paracrine mechanisms, releasing a secretome composed of soluble factors and extracellular vesicles (EVs) that modulate immune responses, regulate osteoblast and osteoclast activity, promote angiogenesis, and support extracellular matrix remodelling. MSC-derived EVs have emerged as key nanoscale mediators that transfer bioactive cargo to target cells in a context-dependent manner, enabling precise regulation of osteoimmune processes. This review summarises current knowledge on the role of MSCs in osteoimmunology, with a focus on how their secretome and EVs integrate immune modulation with bone regeneration. We discuss the mechanisms underlying MSC-mediated regulation of innate and adaptive immune cells, examine emerging cell-free therapeutic strategies based on secretome and EV delivery, and outline the main challenges that must be addressed to advance these approaches towards clinical application.
- 23 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (3) , 1155
Open AccessBridging Osteoimmunology and Regenerative Therapy: The Role of MSCs and Extracellular Vesicles
Bone homeostasis and regeneration depend on tightly regulated interactions between skeletal cells and the immune system within the bone microenvironment. Disruption of this crosstalk by ageing, chronic inflammation, or systemic disease contributes to osteoporosis, inflammatory bone loss, and impaired fracture healing. Osteoimmunology has reframed bone biology as an immune-regulated process, highlighting mesenchymal stem cells (MSCs) as central coordinators of bone-immune communication. Beyond their differentiation capacity, MSCs act primarily through paracrine mechanisms, releasing a secretome composed of soluble factors and extracellular vesicles (EVs) that modulate immune responses, regulate osteoblast and osteoclast activity, promote angiogenesis, and support extracellular matrix remodelling. MSC-derived EVs have emerged as key nanoscale mediators that transfer bioactive cargo to target cells in a context-dependent manner, enabling precise regulation of osteoimmune processes. This review summarises current knowledge on the role of MSCs in osteoimmunology, with a focus on how their secretome and EVs integrate immune modulation with bone regeneration. We discuss the mechanisms underlying MSC-mediated regulation of innate and adaptive immune cells, examine emerging cell-free therapeutic strategies based on secretome and EV delivery, and outline the main challenges that must be addressed to advance these approaches towards clinical application.